ClinicalTrials.gg
Status unknownNCT00003034Updated Nov 6, 2013

ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen

A Phase 3 interventional study of doxorubicin hydrochloride and ranpirnase in Malignant Mesothelioma, sponsored by Alfacell. Status unknown at 19 sites in 4 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2013-11-06.

Sponsored by Alfacell · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2007), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 164 studies in Mesothelioma, Malignant with a site in United States — 21 open to participants now, 37 under way, 1 of them phase 3. Mesothelioma, Malignant · United States.

Planned enrollment
9th of 144
300 · median 33
Started
1997
with 3 others
Phase 3
9 of 164
none open now
Registered
1st of 164
by date

Among the 164 studies in Mesothelioma, Malignant with a site in United States, this one is the 9th largest by planned enrollment of the 144 interventional ones that give a count, is one of 4 that started in 1997, is one of 9 in phase 3, and was the 1st registered.

Mesothelioma, Malignant

339 studies on the registry are indexed under Mesothelioma, Malignant; 63 are open to participants now.

Browse Mesothelioma, Malignant studies →

Open to participants now

21 of the 164 studies in Mesothelioma, Malignant with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 54 Mesothelioma, Malignant studies recruiting now, 42 (78%) set no upper age limit and 5 (9%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Mesothelioma, Malignant with a site in United States, or all of them as a file.
02

Study summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether Onconase plus doxorubicin is more effective than doxorubicin alone in treating patients with malignant mesothelioma.

PURPOSE: This randomized phase III trial is studying doxorubicin alone to see how well it works compared to doxorubicin and Onconase in treating patients with malignant mesothelioma.

Read the detailed description

OBJECTIVES:

  • Compare the efficacy of doxorubicin with or without ranpirnase in patients with malignant pleural or peritoneal mesothelioma.
  • Compare the safety profile of these regimens in these patients.
  • Compare the overall survival, progression-free survival, and quality of life of patients treated with these regimens.

OUTLINE: This is a randomized, open-label, controlled, multicenter study. Patients are stratified according to disease histology (epithelioid vs nonepithelioid) and CALGB groups 1-4. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive ranpirnase IV over 30 minutes weekly followed by doxorubicin IV. Treatment repeats every 3 weeks for at least 6 courses in the absence of disease progression. Patients demonstrating evidence of clinical response or stable disease may continue on maintenance therapy with ranpirnase as a single agent until disease progression.
  • Arm II: Patients receive doxorubicin as in arm I for up to 6 courses. Quality of life is assessed.

PROJECTED ACCRUAL: A minimum of 300 patients will be accrued for this study.

03

Conditions studied

  • Malignant Mesothelioma

Keywords

  • localized malignant mesothelioma
  • advanced malignant mesothelioma
  • recurrent malignant mesothelioma
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DISEASE CHARACTERISTICS:

  • confirmed malignant pleural or peritoneal mesothelioma

    • Measurable or evaluable disease
  • CALGB groups 1-4
  • No

PATIENT CHARACTERISTICS:

Age:

  • 21 and over

Performance status:

  • 0-1

:

  • Not specified

Hematopoietic:

  • WBC greater than 3,500/mm\^3
  • at least 1,500/mm\^3
  • count at least 100,000/mm\^3

Hepatic:

  • no greater than 2 times
  • no greater than 2 mg/dL
  • PT and normal

Renal:

  • Creatinine normal

Cardiovascular:

  • No symptomatic class II-IV cardiovascular disease
  • No congestive heart failure
  • No angina pectoris
  • No cardiac arrhythmias
  • No uncontrolled hypertension
  • No cerebrovascular disease

Metabolic:

  • No serum calcium, phosphate, electrolyte, or other metabolic abnormalities, such as metabolic acidosis

Other:

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective
  • No serious infection
  • No uncontrolled psychosis or neurologic disease (e.g., seizure disorders)
  • No uncontrolled diabetes mellitus
  • No other primary within the past 5 years except nonmelanoma skin cancer
  • No senility or emotional instability

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • No more than one prior systemic chemotherapy regimen
  • No prior doxorubicin
  • At least 6 weeks since prior chemotherapy

Endocrine therapy:

  • Not specified

Radiotherapy:

  • Prior radiotherapy for progressive or recurrent disease allowed except myocardium radiotherapy

Surgery:

  • Prior surgical resection allowed
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Arm I

    Patients receive ranpirnase IV over 30 minutes weekly followed by doxorubicin IV. Treatment repeats every 3 weeks for at least 6 courses in the absence of disease progression. Patients demonstrating evidence of clinical response or stable disease may continue on maintenance therapy with ranpirnase as a single agent until disease progression.

    Drug: doxorubicin hydrochloride · Drug: ranpirnase

  • Experimental
    Arm II

    Patients receive doxorubicin as in arm I for up to 6 courses.

    Drug: doxorubicin hydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. Survival

Secondary outcomes

  1. Objective response

  2. Time to best response

  3. Response duration

07

Study locations

19 sites
  • CCOP - Northern Indiana CR Consortium
    South Bend, Indiana 46601, United States
  • Greenebaum Cancer Center at University of Maryland Medical Center
    Baltimore, Maryland 21201, United States
  • Spectrum Health Hospital - Butterworth Campus
    Grand Rapids, Michigan 49503, United States
  • CCOP - Duluth
    Duluth, Minnesota 55805-1983, United States
  • Missouri Cancer Care, PC at St. Joseph Health Center - St. Charles
    St. Charles, Missouri 63301, United States
  • Methodist Estabrook Cancer Center
    Omaha, Nebraska 68114-4199, United States
  • University of New Mexico Cancer Research and Treatment Center
    Albuquerque, New Mexico 87131-5636, United States
  • Asklepios Fachkliniken Muenchen-Gauting
    Gauting, D-82131, Germany
  • Hospital Grosshansdorf
    Grosshansdorf, D-22927, Germany
  • Asklepios Klinik St. Georg
    Hamburg, D-20099, Germany
  • Asklepios Klinik Harburg
    Hamburg, D-21075, Germany
  • Klinikum Rechts Der Isar - Technische Universitaet Muenchen
    Munich, D-81675, Germany
  • Istituto Nazionale per la Ricerca sul Cancro
    Genoa, 16132, Italy
  • Ospedale San Martino
    Genoa, 16132, Italy
  • Fondazione I.R.C.C.S. Policlinico San Matteo
    Pavia, 27100, Italy
  • Medical University of Gdansk
    Gdansk, 80-211, Poland
  • University School of Medical Sciences
    Poznan, PL-60 569, Poland
  • Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
    Warsaw, 02-781, Poland
  • Klinika Chrorob Pluc I Gruzlicy
    Zabrze, 41-803, Poland
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 1997 and a primary completion of Feb 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 1999
First posted
Jan 27, 2003
Start
May 1997
Primary completionEst.
Feb 2008
Last update
Nov 6, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00003034
Lead sponsor
Alfacell
First posted
Jan 27, 2003
Start date
May 1997
Primary completion
Feb 2008 (estimated)
Last update
Nov 6, 2013

Study contacts

Diane Scudiery
study chair · Alfacell
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doxorubicin

Start the discussion